Rossari Biotech Q3 FY26: Revenue +13%, Saudi plan

Update overview: board meeting and filings

Rossari Biotech Limited disclosed a set of board and investor updates around its Q3 FY26 results cycle, with an update shared on 09 April 2026. A board meeting was scheduled for January 17, 2026 at 12:30 PM IST to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Alongside the results, the agenda included corporate actions and strategic proposals spanning capacity expansion, ESOP-related share allotment, and asset rationalisation. The company also indicated compliance steps such as trading window restrictions around the results announcement.

What the board was scheduled to consider on January 17, 2026

The January 17 meeting agenda included the approval of unaudited standalone and consolidated financial results for Q3 and the nine months ended December 31, 2025. The board was also set to consider in-principle approval for setting up greenfield manufacturing facilities under Rossari International Limited, a wholly owned subsidiary. Another item was the proposed allotment of equity shares under the Rossari Employee Option Plan 2019. In addition, the board was to evaluate the sale of office premises at Kanjurmarg, Mumbai, and the potential closure of Rossari Bangladesh Limited, a wholly owned subsidiary.

Trading window closure tied to results

Rossari Biotech stated that the “Trading Window” for dealing in the company’s securities would be closed for all designated persons and their immediate relatives under the insider trading code. The closure period was from January 01, 2026 until 48 hours after the announcement of the unaudited financial results. The company referenced compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including Regulations 29 and 33.

Q3 FY26 performance: revenue growth, margins, and exports

For Q3 FY26, Rossari Biotech reported consolidated revenue of ₹581.7 crore, a 13% year-on-year increase. EBITDA for the quarter was ₹68.9 crore, up 6%, with an EBITDA margin of 11.8%. Profit after tax (PAT) was reported at ₹32.8 crore, up 3.5% year-on-year, with a PAT margin of 5.6%. The company also highlighted that export contribution reached 33% of turnover in Q3 and 30% for the nine months.

Why profitability was pressured despite growth

The company indicated that profitability was impacted by ongoing investments aimed at expanding capacity, accelerating product development, and seeding markets. It also flagged higher employee costs linked to the implementation of new labour codes. In its outlook, Rossari Biotech said operating leverage from new capacities is expected to materialise by FY27 as the ramp-up continues. It added that margins are projected to remain in the 12%-13% range until ethylene oxide supply normalises, with a potential improvement if the B2C business is restructured.

Greenfield capacity: Saudi Arabia specialty chemicals facility

As part of the board outcomes referenced in the update, the board granted in-principle approval for a greenfield specialty chemicals facility in Saudi Arabia. The company positioned the proposal as a step to strengthen supply chain resilience and support international growth. It also said the proposed facility is expected to enhance supply capabilities, accelerate speed-to-market, and strengthen its position in specialty chemicals, subject to regulatory approvals.

ESOP 2019 allotment and paid-up capital change

The board approved the allotment of 2,000 equity shares under the Rossari Employee Option Plan 2019. Following this allotment, the company stated that paid-up capital increased to ₹11,07,66,732. The ESOP-related action was part of the same board meeting outcome set that covered results and corporate approvals.

Asset rationalisation: Kanjurmarg office premises sale

Rossari Biotech approved the sale of non-operational office premises at Kanjurmarg, Mumbai, for ₹25 crore. The company stated that the transaction would have no impact on business operations. The board agenda also referenced evaluation of the potential closure of Rossari Bangladesh Limited, a wholly owned subsidiary.

Other corporate actions: Singapore subsidiary

In a separate disclosure context tied to the January 17, 2026 board meeting intimation, Rossari Biotech stated that the board approved the incorporation of a wholly owned subsidiary in the Republic of Singapore. This was disclosed as part of “other matters” approved by the board.

Earnings call schedule and investor communication

Rossari Biotech scheduled an earnings conference call for January 19, 2026 at 4:00 PM IST to discuss Q3 FY26 financial results with investors and analysts. The company also referenced an earnings presentation for Q3 and nine months FY26, and a press release dated January 17, 2026 titled “Rossari Biotech announces Q3 FY 26 Results.” Separately, it mentioned newspaper publication of extracts of consolidated unaudited financial results for the quarter and nine months ended December 31, 2025.

Quick comparison: Q2 FY26 versus Q3 FY26

The broader set of disclosures also included Q2 FY26 quarterly results details. In Q2 FY26, revenue from operations was reported at ₹586.1 crore versus ₹498.4 crore a year earlier, an 18% rise. EBITDA for Q2 FY26 was ₹71.9 crore versus ₹65.9 crore, with EBITDA margin at 12.3% compared with 13.2%. PAT for Q2 FY26 was ₹36.9 crore versus ₹35.3 crore, and diluted EPS was ₹6.7 versus ₹6.4.

Capex and medium-term operating leverage

Rossari Biotech said CapEx capitalised in FY26 totalled around ₹200 crore. The company linked the current profitability profile to investments in capacity expansion and product development, and guided that operating leverage is expected to show up by FY27 as new capacities ramp up. It also noted that exports are expected to continue outpacing domestic growth, supported by expansion into new geographies and products, and that new R&D products and biosurfactants approvals by global MNCs are expected to support margins and growth.

Key dates referenced in the disclosures

The disclosures referenced multiple dates spanning results communication and compliance.

What to watch next

The near-term focus remains on execution against the capacity and international expansion roadmap described by the company, including the Saudi Arabia greenfield facility that is subject to regulatory approvals. Investors will also track how margin guidance evolves in the context of ethylene oxide supply conditions and the company’s stated view on potential B2C restructuring. On the corporate side, the follow-through on the Kanjurmarg asset sale and any decision on Rossari Bangladesh Limited would be key monitoring items from the board agenda and outcomes referenced.